|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.548 EUR | +0.91% |
|
-0.51% | -3.37% |
| 07-21 | Innate Pharma Completes Enrollment in Dose Escalation of Phase 1 Study of IPH4502 | CI |
| 07-21 | Innate Pharma Closes Enrollment in Phase 1 Advanced Solid Tumors Study | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Neutral |
| Resistance | 1.71 | 1.96 | 1.85 |
| Spread/Res. | -9.47% | -21.02% | -16.32% |
| Spread/Supp. | +3.06% | +6.61% | +44.13% |
| Support | 1.502 | 1.452 | 1.074 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- IPH Stock
- Charts Innate Pharma
Select your edition
All financial news and data tailored to specific country editions
